Ridgeline Therapeutics is focused on developing innovative small molecule inhibitors targeting nicotinamide N-methyltransferase (NNMT), an enzyme that plays a crucial role in energy metabolism and epigenetic regulation. Elevated levels of NNMT are associated with various chronic conditions, including obesity, Type 2 diabetes, and muscular dystrophies. By inhibiting NNMT, Ridgeline aims to address the underlying metabolic dysfunctions that contribute to these diseases, thereby promoting better health outcomes. Their approach is grounded in cutting-edge research on cellular metabolism and epigenetics, which informs the design of their drug candidates.

The company is advancing a pipeline of therapies aimed at treating a range of conditions, including age-related muscle weakness (sarcopenia), obesity, Type 2 diabetes, muscle atrophy, glioblastoma, and Duchenne muscular dystrophy. Ridgeline's drug candidates are designed to be taken once daily and are intended to provide significant benefits over existing treatment options. For instance, their obesity treatment aims to facilitate substantial and sustained weight loss, while their therapies for muscle-related disorders seek to restore muscle strength and improve quality of life. Through these efforts, Ridgeline Therapeutics is positioned to make a meaningful impact on chronic health issues that affect millions globally.

United States

Ridgeline Therapeutics is a Houston-based biotech company developing safe and effective drugs that selectively target new mechanisms-of-action to reverse age-related muscle degeneration.

Ridgeline Therapeutics

Company Details